A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression

被引:879
作者
Keller, MB
McCullough, JP
Klein, DN
Arnow, B
Dunner, DL
Gelenberg, AJ
Markowitz, JC
Nemeroff, CB
Russell, JM
Thase, ME
Trivedi, MH
Zajecka, J
Blalock, JA
Borian, FE
Jody, DN
DeBattista, C
Koran, LM
Schatzberg, AF
Fawcett, J
Hirschfeld, RMA
Keitner, G
Miller, I
Kocsis, JH
Kornstein, SG
Manber, R
Ninan, PT
Rothbaum, B
Rush, AJ
Vivian, D
Rothbaum, B
机构
[1] Brown Univ, Dept Psychiat, Providence, RI 02906 USA
[2] Virginia Commonwealth Univ, Dept Psychol, Unipolar Mood Disorders Inst, Richmond, VA 23284 USA
[3] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA
[4] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA
[5] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[6] Univ Arizona, Dept Psychiat, Tucson, AZ USA
[7] Cornell Univ, Coll Med, Dept Psychiat, New York, NY USA
[8] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA
[9] Univ Texas, Med Branch, Dept Psychiat & Behav Sci, Galveston, TX 77550 USA
[10] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA
[11] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA
[12] Rush Presbyterian St Lukes Med Ctr, Dept Psychiat, Chicago, IL 60612 USA
[13] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Bristol Myers Squibb Co, Plainsboro, NJ USA
关键词
D O I
10.1056/NEJM200005183422001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. Methods: We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item Hamilton Rating Scale for Depression (indicating clinically significant depression). Remission was defined as a score of 8 or less at weeks 10 and 12. For patients who did not have remission, a satisfactory response was defined as a reduction in the score by at least 50 percent from base line and a score of 15 or less. Raters were unaware of the patients' treatment assignments. Results: Of the 681 patients, 662 attended at least one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in both the nefazodone group and the psychotherapy group, as compared with 73 percent in the combined-treatment group (P<0.001 for both comparisons). Among the 519 subjects who completed the study, the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy group, as compared with 85 percent in the combined-treatment group (P<0.001 for both comparisons). The rates of withdrawal were similar in the three groups. Adverse events in the nefazodone group were consistent with the known side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness). Conclusions: Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone. (N Engl J Med 2000;342:1462-70.) (C)2000, Massachusetts Medical Society.
引用
收藏
页码:1462 / 1470
页数:9
相关论文
共 38 条
[1]  
*AG HLTH CAR POL R, 1993, AHCPR PUBL
[2]  
[Anonymous], 1993, AM J PSYCHIAT, V150, P1
[3]  
Beck, 1979, COGNITIVE THERAPY DE
[4]   THE IMPORTANCE OF MEASURES OF AFFECTIVE TEMPERAMENTS IN GENETIC-STUDIES OF MOOD DISORDERS [J].
CASSANO, GB ;
AKISKAL, HS ;
PERUGI, G ;
MUSETTI, L ;
SAVINO, M .
JOURNAL OF PSYCHIATRIC RESEARCH, 1992, 26 (04) :257-268
[5]  
CONTE HR, 1986, ARCH GEN PSYCHIAT, V43, P471
[6]  
FAWCETT J, 1987, PSYCHOPHARMACOL BULL, V23, P309
[7]   Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression [J].
Feiger, AD ;
Bielski, RJ ;
Bremner, J ;
Heiser, JF ;
Trivedi, M ;
Wilcox, CS ;
Roberts, DL ;
Kensler, TT ;
McQuade, RD ;
Kaplita, SB ;
Archibald, DG .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (01) :19-28
[8]  
First M, 1994, STRUCTURED CLIN INTE
[9]  
GARLOW SJ, 2000, KAPLAN SADOCKS COMPR, V2, P2412
[10]  
GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405